A detailed summary of maple syrup urine disease

Maple syrup urine disease (MSUD), also known as branched-chain ketoaciduria, is a rare and inherited metabolic disorder characterized by the inability to effectively metabolize branched-chain amino acids (BCAAs), including leucine, isoleucine, and valine. This genetic disorder is inherited in an autosomal recessive manner, with mutations in specific genes impairing the activity of enzymes responsible for BCAA breakdown. MSUD leads to the accumulation of these amino acids in the blood and tissues, resulting in a range of clinical manifestations. Early onset of an acute encephalopathy in the newborn period, characterized by lethargy, hypertonia, poor feeding, and ketoacidosis, necessitates prompt treatment to avoid lifelong neurological damage or even death. Effective dietary regulation of the BCAAs can be associated with appropriate growth; nevertheless, acute decompensation due to acute dietary protein loading, catabolic protein insults related to other chronic diseases, infection, exercise, injury, and physiological stress must be managed on a continuous basis. The effects of infants delivered to women with MSUD necessitate strict nutritional monitoring throughout pregnancy. Liver transplantation has proven to be beneficial. This paper provides a comprehensive overview of MSUD, emphasizing the clinical manifestations, genetic basis, and management strategies for this rare metabolic disorder.